Mohammad Arastoo

TauBioGenix, a prospective University of Aberdeen spin-out, seeks £2M seed funding to advance hS1D12, a humanised, potential best-in-class anti-tau immunotherapy for the indication of Alzheimer’s disease and related tauopathies.